PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
9730262-4	1998	Procainamide and NAPA progressively reduced vagal stimulation-induced bradycardia in chloralose-anaesthetized dogs.	Chloralose	85-95	NSF attachment protein alpha	Canis lupus familiaris	17-21
2464811-3	1989	EERs were recorded during bipolar and unipolar pacing rates of 120, 150, and 200/min before and during a five step PA or NAPA infusion which resulted in progressively increasing PA and NAPA plasma concentrations (Cps), 1.7-32.5 mg/l for PA and 8.1-116.1 mg/l for NAPA.	Procainamide	123-125	NSF attachment protein alpha	Canis lupus familiaris	185-189
1708063-1	1991	The electrophysiologic effects of N-acetylprocainamide (NAPA), a metabolite of procainamide reported to exert significant Class III antiarrhythmic effects in the adult heart, were evaluated in 12 neonatal mongrel canines (ages 7-14 days).	Procainamide	42-54	NSF attachment protein alpha	Canis lupus familiaris	56-60
2464811-3	1989	EERs were recorded during bipolar and unipolar pacing rates of 120, 150, and 200/min before and during a five step PA or NAPA infusion which resulted in progressively increasing PA and NAPA plasma concentrations (Cps), 1.7-32.5 mg/l for PA and 8.1-116.1 mg/l for NAPA.	Procainamide	123-125	NSF attachment protein alpha	Canis lupus familiaris	185-189
2464811-3	1989	EERs were recorded during bipolar and unipolar pacing rates of 120, 150, and 200/min before and during a five step PA or NAPA infusion which resulted in progressively increasing PA and NAPA plasma concentrations (Cps), 1.7-32.5 mg/l for PA and 8.1-116.1 mg/l for NAPA.	Procainamide	123-125	NSF attachment protein alpha	Canis lupus familiaris	185-189
2464811-3	1989	EERs were recorded during bipolar and unipolar pacing rates of 120, 150, and 200/min before and during a five step PA or NAPA infusion which resulted in progressively increasing PA and NAPA plasma concentrations (Cps), 1.7-32.5 mg/l for PA and 8.1-116.1 mg/l for NAPA.	Procainamide	123-125	NSF attachment protein alpha	Canis lupus familiaris	185-189
2438320-5	1987	Both NAPA and quinidine immediately prolonged the atrial flutter cycle length in all dogs, from 118 +/- 15 to 141 +/- 18 ms and from 119 +/- 17 to 153 +/- 21 ms, respectively (both p less than 0.001), and then terminated atrial flutter in 11 of the 12 NAPA studies and in 6 of the 10 quinidine studies.	Quinidine	14-23	NSF attachment protein alpha	Canis lupus familiaris	252-256
2447406-3	1987	Procainamide was 1.2-1.5 times more potent than NAPA in this regard.	Procainamide	0-12	NSF attachment protein alpha	Canis lupus familiaris	48-52
2447406-7	1987	Taken together, these results on atrial rate, ventricular rate, and mean blood pressure indicate that the two drugs possess distinct pharmacological properties--i.e., procainamide exhibits slightly more marked direct vagolytic and depressor effects than does NAPA and exerts quite different blood pressure effects from those of NAPA.	Procainamide	167-179	NSF attachment protein alpha	Canis lupus familiaris	259-263
2447406-7	1987	Taken together, these results on atrial rate, ventricular rate, and mean blood pressure indicate that the two drugs possess distinct pharmacological properties--i.e., procainamide exhibits slightly more marked direct vagolytic and depressor effects than does NAPA and exerts quite different blood pressure effects from those of NAPA.	Procainamide	167-179	NSF attachment protein alpha	Canis lupus familiaris	328-332
2438320-5	1987	Both NAPA and quinidine immediately prolonged the atrial flutter cycle length in all dogs, from 118 +/- 15 to 141 +/- 18 ms and from 119 +/- 17 to 153 +/- 21 ms, respectively (both p less than 0.001), and then terminated atrial flutter in 11 of the 12 NAPA studies and in 6 of the 10 quinidine studies.	Quinidine	284-293	NSF attachment protein alpha	Canis lupus familiaris	5-9
2433968-9	1986	On the other hand, pretreatment with propranolol blocked and reversed the inotropic actions of NAPA 60 mg/kg, and potentiated its negative chronotropic effects.	Propranolol	37-48	NSF attachment protein alpha	Canis lupus familiaris	95-99
6175815-1	1982	The hypotensive effects of N-acetylprocainamide (NAPA) were studied in anesthetized dogs and in a normal subject.	Acecainide	27-47	NSF attachment protein alpha	Canis lupus familiaris	49-53
2431636-5	1986	In 2 dogs (previously used in part II), N-acetylprocainamide (NAPA) was administered IV at a dose of 10 mg/kg.	Acecainide	40-60	NSF attachment protein alpha	Canis lupus familiaris	62-66
6191146-2	1983	The purpose of the present study was to determine if N-acetylprocainamide (NAPA), an active metabolite of procainamide which has been proposed as an effective and less toxic alternative, would exert an equivalent degree of vagal blockade.	Procainamide	61-73	NSF attachment protein alpha	Canis lupus familiaris	75-79
6167356-1	1981	The major metabolite of procainamide (PA) is N-acetylprocainamide (NAPA).	Procainamide	24-36	NSF attachment protein alpha	Canis lupus familiaris	67-71
6167356-1	1981	The major metabolite of procainamide (PA) is N-acetylprocainamide (NAPA).	Procainamide	38-40	NSF attachment protein alpha	Canis lupus familiaris	67-71
6158076-3	1980	infusion of 20 mg/kg NAPA.HCl.	Hydrochloric Acid	26-29	NSF attachment protein alpha	Canis lupus familiaris	21-25
6153717-4	1980	In fact, at some doses PA and NAPA accentuated the pressor and positive chronotropic effects of epinephrine.	Epinephrine	96-107	NSF attachment protein alpha	Canis lupus familiaris	30-34
6167356-1	1981	The major metabolite of procainamide (PA) is N-acetylprocainamide (NAPA).	Acecainide	45-65	NSF attachment protein alpha	Canis lupus familiaris	67-71